MEDICLINIC INTERNATIONAL PLC - Announcement of the annual general meeting poll results

Release Date: 26/07/2018 08:00
Code(s): MEI
 
Wrap Text
Announcement of the annual general meeting poll results

Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
(“Mediclinic”, the “Company” or the “Group”)

26 July 2018

ANNOUNCEMENT OF THE ANNUAL GENERAL MEETING POLL RESULTS

Mediclinic announces that at its Annual General Meeting (“AGM”) held on 25 July 2018, all resolutions set out in the notice of the AGM were passed by the
requisite majority of votes by shareholders by way of poll. The results of the poll for each resolution were as follows:

                                            TOTAL           % OF ISSUED       VOTES FOR       %           VOTES            %           VOTES
                                            SHARES          SHARE CAPITAL                                 AGAINST                      WITHHELD
                                            VOTED           VOTED
      ORDINARY RESOLUTIONS
1.    To receive the Company’s              625,083,123     84.79             625,071,801     100.00      11,322           0.00        756,974
      financial statements and the
      reports by the Directors and
      auditors
2.    To approve the Directors’             624,930,678     84.77             584,591,036     93.54       40,339,642       6.46        909,418
      Remuneration Report
3.    To declare a final dividend of 4.70   625,551,249     84.85             625,538,743     100.00      12,506           0.00        288,848
      pence per ordinary share
4.    To elect Dr Ronnie van der Merwe      625,545,985     84.85             624,986,007     99.91       559,978          0.09        294,112
      as a Director
5.    To elect Dr Muhadditha Al             625,545,570     84.85             625,118,233     99.93       427,337          0.07        294,527
      Hashimi as a Director
6.    To elect Dr Felicity Harvey as a      625,546,210     84.85             625,119,604     99.93       426,606          0.07        293,887
      Director
7.    To re-elect Jurgens Myburgh as a      625,545,985     84.85             624,155,541     99.78       1,390,444        0.22        294,112
      Director
8.    To re-elect Dr Edwin Hertzog as a     623,687,848     84.60             607,348,527     97.38       16,339,321       2.62        2,152,247
      Director
9.    To re-elect Jannie Durand as a        625,264,107     84.81             612,530,823     97.96       12,733,284       2.04        575,989
      Director
10.   To re-elect Alan Grieve as a          622,786,782     84.48             621,642,338     99.82       1,144,444        0.18        3,053,315
      Director
11.   To re-elect Seamus Keating as a       622,785,782     84.47             622,271,752     99.92       514,030          0.08        3,054,315
      Director
12.   To re-elect Trevor Petersen as a      622,786,512     84.47             620,324,982     99.60       2,461,530        0.40        3,053,585
      Director
13.   To re-elect Desmond Smith as a        621,209,703     84.26             551,631,116     88.80       69,578,587       11.20       4,630,393
      Director
14.   To re-elect Danie Meintjes as a       625,545,985     84.85             603,084,758     96.41       22,461,227       3.59        294,112
      Director
15.   To re-appoint                         622,507,013     84.44             618,004,417     99.28       4,502,596        0.72        3,333,084
      PricewaterhouseCoopers LLP as
      auditors of the Company
16.   To authorise the Audit and Risk       625,265,419     84.81             624,782,389     99.92       483,030          0.08        574,678
      Committee to determine the
      remuneration of the auditors
17.   To authorise the Directors to         624,054,992     84.65             560,842,274     89.87       63,212,718       10.13       1,785,104
      make political donations
18.   To authorise the Directors to allot   625,265,198     84.81             524,756,458     83.93       100,508,740      16.07       574,899
      ordinary shares
      SPECIAL RESOLUTIONS
19.   To authorise the Directors to dis-    625,262,700     84.81             590,059,495     94.37       35,203,205       5.63        577,397
      apply the statutory pre-emption
      rights
20.   To authorise the Directors to dis-    625,263,385     84.81             591,029,782     94.52       34,233,603       5.48        576,711
      apply pre-emption rights for
      purposes of acquisitions or capital
      investments
21.   To approve the reduction in           624,328,189     84.68             602,771,765     96.55       21,556,424       3.45        1,511,908
      minimum notice period for general  
      meetings (other than annual
      general meetings)

VOTES OF SHAREHOLDERS EXCLUDING THE CONTROLLING SHAREHOLDER ON ELECTION AND RE-ELECTION OF INDEPENDENT NON-EXECUTIVE DIRECTORS

      ORDINARY RESOLUTIONS                  TOTAL           % OF ISSUED       VOTES FOR       %           VOTES            %           VOTED
                                            SHARES          SHARE CAPITAL                                 AGAINST                      WITHHELD
                                            VOTED           VOTED
5.    To elect Dr Muhadditha Al             369,163,066     76.77             368,735,729     99.88       427,337          0.12        294,527
      Hashimi as a Director
6.    To elect Dr Felicity Harvey as a      369,163,706     76.77             368,737,100     99.88       426,606          0.12        293,887
      Director
10.   To re-elect Mr Alan Grieve as a       366,404,278     76.20             365,259,834     99.69       1,144,444        0.31        3,053,315
      Director
11.   To re-elect Mr Seamus Keating as      366,403,278     76.20             365,889,248     99.86       514,030          0.14        3,054,315
      a Director
12.   To re-elect Mr Trevor Petersen as     366,404,008     76.20             363,942,478     99.33       2,461,530        0.67        3,053,585
      a Director
13.   To re-elect Mr Desmond Smith as       364,827,199     75.87             295,248,612     80.93       69,578,587       19.07       4,630,393
      a Director

Notes:
1.       Any proxy appointments giving discretion to the Chairman of the Meeting have been included in the "For" total.
2.       A vote "Withheld" is not a vote in law and is not counted in the calculation of the votes "For" or "Against" a resolution.
3.       The Company's total ordinary shares in issue (total voting rights) as at 25 July 2018 was 737 243 810 ordinary shares of 10 pence each.
         Ordinary shareholders are entitled to one vote per ordinary share held.
4.       As the Company has a controlling shareholder, Remgro Limited, as defined in the Financial Conduct Authority's Listing Rules, each
         resolution to elect an independent non-executive director (resolutions 5 to 6 and 10 to 13) have under Listing Rule 9.2.2E been approved
         by a majority of the votes cast by:
         (a) the shareholders of the Company as a whole; and
         (b) the independent shareholders of the Company, that is, all the shareholders entitled to vote on each resolution, excluding the
         controlling shareholder.

In accordance with paragraph 9.6.2 of the Listing Rules, a copy of the resolutions passed at the meeting has been submitted to the National Storage
Mechanism and will shortly be available for inspection at http://www.morningstar.co.uk/uk/NSM.

The complete poll results and details of proxy votes lodged before the AGM will be available shortly on the Investor Relations section of the Company’s
website at http://ir.mediclinic.com.

About Mediclinic International plc

Mediclinic is an international private healthcare services group with operating divisions in Switzerland, Southern Africa (South Africa and Namibia) and the
United Arab Emirates. Its core purpose is to enhance the quality of life of patients by providing acute care, specialist-orientated, multi-disciplinary healthcare
services. Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, an LSE-listed and UK-based private healthcare group.

Mediclinic comprises 75 hospitals and 30 clinics. Hirslanden operates 17 private acute care facilities and 4 clinics in Switzerland with more than 1 800
inpatient beds; Mediclinic Southern Africa operates 49 hospitals and 2 day clinics throughout South Africa and 3 hospitals in Namibia with more than 8 100
inpatient beds in total; and Mediclinic Middle East operates 6 hospitals and 24 clinics with more than 700 inpatient beds in the United Arab Emirates.

Mediclinic has a primary listing on the Main Market of the LSE in the United Kingdom, with secondary listings on the JSE in South Africa and the NSX in
Namibia.”

Company Secretary, Link Company Matters Limited
Jayne Meacham / Caroline Emmet
+44 (0)20 7954 9569

Investor Relations, Mediclinic International plc
James Arnold, Head of Investor Relations
ir@mediclinic.com
+44 (0)20 3786 8181

Media queries
FTI Consulting
Brett Pollard/Debbie Scott – UK
+44 (0)20 3727 1000
Sherryn Schooling – South Africa
+27 (0)21 487 9000
Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom
Website: www.mediclinic.com
Joint corporate brokers: Morgan Stanley & Co International plc and UBS Investment Bank
JSE sponsor: Rand Merchant Bank (A division of FirstRand Bank Limited)
NSX sponsor: Simonis Storm Securities (Pty) Ltd

Date: 26/07/2018 08:00:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.

Email this JSE Sens Item to a Friend.

Share This Story